Genomic Health says data support expanded use of Oncotype DX tests Genomic Health announced the presentation of data that support expanded use of the Oncotype DX tests in optimizing treatment decisions for breast and colon cancer patients at various stages of disease. The new data confirm the ability of the Oncotype DX colon cancer test to predict recurrence risk in stage II and stage III colon cancer patients, and exploratory analyses have identified 16 genes strongly associated with oxaliplatin treatment benefit. Additionally, two studies reconfirm the clinical utility of the Oncotype DX breast cancer test in treatment decision making in women with early-stage invasive breast cancer. The study results are being presented at the 2012 European Society for Medical Oncology Congress taking place September 28-October 2.
News For GHDX From The Last 14 Days
Check below for free stories on GHDX the last two weeks.